Investor Presentaiton
ASCEND Program-Level Cardiovascular Safety Data
MACE profile was generally consistent across treatment groups in all trials*
Patients with events
n/N (%)
Rate per 100 PY
(95% CI)
Favors
Daprodustat
Favors
ESA
MACE
Daprodustat
ESA+
Daprodustat
ESA+
ASCEND-ND
378/1937
(19.5)
374/1487
371/1935
(19.2)
394/1477
10.86
(9.80, 12.02)
10.63
H
Absolute rate difference
per 100 PY (95% CI)
0.23 (-1.31, 1.77)
(9.58, 11.77)
11.07
11.86
ASCEND-D
-0.78 (-2.41, 0.84)
HH
(25.2)
(26.7)
(9.98, 12.26)
(10.72, 13.09)
19/157
15/155
ASCEND-ID
(12.1)
(9.7)
33/270
14/137
ASCEND-TD
(12.2)
(10.2)
11.65
(7.02, 18.20)
12.30
(8.46, 17.27)
9.24
(5.17, 15.24)
2.41 (-4.61, 9.43)
10.02
(5.48, 16.81)
2.28 (-4.44, 9.00)
0
5
10
15
20
-10
-5
0
5
10
15
Rate per 100 PY (95% CI)
Absolute rate difference per 100 PY (95% CI)
First MACE rates in ASCEND-NHQ (28 weeks): 4.9% daprodustat; 6.2% placebo
*Smaller trials (ASCEND-ID, ASCEND-TD and ASCEND-NHQ) reported MACE but were not designed for formal MACE evaluation; †Darbepoetin alfa (ASCEND-D, -ND, -ID),
epoetin alfa (ASCEND-D, -TD).
17View entire presentation